Entry Point Capital, LLC Phathom Pharmaceuticals, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 8,503 shares of PHAT stock, worth $153,054. This represents 0.13% of its overall portfolio holdings.
Number of Shares
8,503
Previous 19,380
56.12%
Holding current value
$153,054
Previous $206 Million
57.45%
% of portfolio
0.13%
Previous 0.18%
Shares
2 transactions
Others Institutions Holding PHAT
# of Institutions
126Shares Held
59.6MCall Options Held
467KPut Options Held
34.9K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$182 Million6.14% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$134 Million28.04% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$62.9 Million4.3% of portfolio
-
Invesco Ltd. Atlanta, GA3.14MShares$56.6 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$52.7 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $705M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...